Enzymatica AB

Quotes

ColdZyme is the future of cold relief. By breaking the viral cycle at the first signs of symptoms, the product helps cut illness duration in half and speeds up recovery.

Sana Alajmovic

We offer a unique, evidence-based alternative in a market dominated by outdated products. ColdZyme reduces viral load by 94 percent, helping you avoid putting your life on hold.

Sana Alajmovic

My focus is to lead Enzymatica into its next phase of growth. ColdZyme is a consumer favorite with clinically proven efficacy – we have the potential to become a global leader.

Sana Alajmovic

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

Tue, Apr 29, 2025 08:30 CET

First quarter · Net sales amounted to SEK 12.3million (9.4). · Operating result amounted to SEK-18.0 million (-18.4) · Earnings per share, before and afterdilution, amounted to SEK -0.07 (-0.11). · Cash flow from operating activitiesamounted to SEK -8.5 million (-7.3). Comments from CEO Claus Egstrand "Enzymatica’s progress and future prospects are clearly reflected in the strong first quarter of 2025. ColdZyme continues to perform strongly in the pharmacy sector, growing faster than the overall market and resulting in additional

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

Quotes

Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

Subscribe